At the 2019 New Mexico Medical Cannabis Conference you will have the opportunity to choose which presentations you would like to see. Please note that all presentations other than the keynote are first come first served and limited seats are available per each presentation. The schedule for the day will be added late January.
KEYNOTE: REBRANDING THE WAR ON DRUGS
Tiffany Bowden, MA, PhD, traces the history of cannabis campaigns and intentional spread of misinformation. She will also discuss implications of research suppression, distinction of plant classifications and components, treatment options, legalization by political party trends and the effects of criminalization of minorities in our country.
Dr. Mikhail (Misha) Kogan
MEDICAL CANNABIS – MANAGEMENT OF ALZHEIMER’S AND PARKINSON’S DISEASE
The neurodegenerative conditions such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) do not have effective disease modifying treatments. In this presentation Dr. Mikhail (Misha) Kogan will summarize current best evidence of ECS dysregulation and utilization of exogenous cannabinoids as part of integrative treatment plan for patients with AD and PD. The discussion will include both disease modifying and symptoms management strategies.
SELECTING A SAFE AND CLEAN CANNABIS PRODUCT
With 46 states having some form of a medical cannabis program to date, we are experiencing a “green rush”. How do you select the best cannabis products for yourself, or if you are a caregiver, for your loved one? In this presentation Sebastien Cotte covers three main principals to follow when buying cannabis products in hopes of giving parents/patients a little extra peace of mind.
WHAT IS THE ENTOURAGE EFFECT, AND WHY DOES IT MATTER?
Mara Gordon shares that twenty years ago, the godfather of cannabinoid science, Professor Raphael Mechoulam, coined the term, “This effect (‘entourage effect’) may represent a novel route for molecular regulation of endogenous cannabinoid activity.” We have since used the term to describe the synergy between various cannabinoids, such as THC and CBD, as well as cannabinoids and terpenes. In the ensuing years we have seen tremendous evidence that the combined properties not only modulate the way cannabis feels when consumed, but also impacts the way in which the body responds at a cellular level.
Dr. Debra Kimless
SHOULD CBD BE CONSIDERED A FIRST LINE THERAPY FOR THE TREATMENT OF MILD TO MODERATE PAIN?
Dr. Debra Kimless will discuss CBD’s pain relieving mechanism of action and then describe and present the findings of a patient trial using a sublingual preparation of CBD, PEA and terpenes for the treatment of mild to moderate pain.
Stay tuned for the announcement of the final list of presenters.
BECOME A PARTNER
This event is only made possible by our partners who are dedicated to ensuring our community has access to high level medical cannabis information.